Amneal's Esomeprazole Strontium 49.3 mg delayed-release capsules now available for GERD patients

Amneal Pharmaceuticals LLC today announced the launch of its branded Esomeprazole Strontium 49.3 mg delayed-release capsules. Esomeprazole Strontium contains the same active moiety (esomeprazole) in a different salt form as found in the branded proton-pump inhibitor Nexium^® (esomeprazole magnesium) and is a new option for adult patients for the short term treatment of gastroesophageal reflux disease (GERD). Amneal is marketing the 505(b)(2) product in the United States under an exclusive license and distribution agreement with Hanmi Pharmaceutical Co. Ltd of South Korea.

Each 49.3 mg strength Esomeprazole Strontium capsule provides the equivalent of 40 mg of esomeprazole base - an equivalent amount of esomeprazole that is present in the corresponding Nexium^® dose. Esomeprazole Strontium capsules are offered in 30-count bottles.

Manufactured in the United States, Esomeprazole Strontium will start shipping Wednesday, December 18^th through the three major U.S. pharmaceutical wholesalers.